Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF

Nora Möhn, MD,* Steffen Pfeuffer, MD,* Tobias Ruck, MD, Catharina C. Gross, PhD, Thomas Skripuletz, MD, Luisa Klotz, MD, Heinz Wiendl, MD, Martin Stangel, MD,* and Sven G. Meuth, MD, PhD*

Neurol Neuroimmunol Neuroinflamm 2020;7:e654. doi:10.1212/NXI.0000000000000654

Abstract

Objective

The use of alemtuzumab, a humanized monoclonal anti-CD52 antibody has changed the therapy of highly active relapsing-remitting MS (RRMS). Alemtuzumab infusion depletes most lymphocytes in peripheral blood, whereas differential recovery of immune cells, probably those with a less CNS-autoreactive phenotype, is supposed to underlie its long-lasting effects. To determine whether alemtuzumab significantly reduces immunoglobulin levels in blood and CSF of treated patients, we analyzed blood and CSF samples of 38 patients with MS treated with alemtuzumab regarding changes in immunoglobulin levels.

Methods

Blood and CSF samples of patients were collected at the beginning of alemtuzumab treatment and at 12, 24, and 36 months after the first administration of the drug. Specimens were analyzed regarding immunoglobulin concentrations in blood and CSF.

Results

We observed significant and dose-dependent reductions of immunoglobulin levels (IgG, IgM, and IgA) in serum and CSF 12 and 24 months following 2 courses of alemtuzumab. Patients with persistent or returning disease activity who were treated with a third course of alemtuzumab exhibited even further decrease in IgG levels compared with matched controls treated twice. Here, alemtuzumab-treated patients with IgG levels below the lower limits of normal were more susceptible to pneumonia, sinusitis, and otitis, whereas upper respiratory tract and urinary tract infections were not associated therewith.

Conclusions

Our results suggest to monitor IgG levels for safety reasons in patients treated with alemtuzumab—in particular when additional treatment courses are required—and to consider preventive action in critical cases.

Classification of evidence

This study provides Class IV evidence that for patients with RRMS alemtuzumab reduces immunoglobulin levels.

*These authors contributed equally as first and senior authors, respectively.

From the Department of Neurology and Clinical Neuroimmunology and Neurochemistry (N.M., T.S., M.S.), Hannover Medical School, Hannover, Germany; and Neurology Clinic with Institute of Translational Neurology (S.P., T.R., C.C.G., L.K., H.W., S.G.M.), University of Münster, Münster, Germany.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Alemtuzumab was approved for therapy of active relapsing-remitting MS (RRMS) in Europe in November 2014.\(^1\)–\(^3\) The humanized monoclonal antibody selectively binds CD52, a human glycosylphosphatidylinositol-anchored protein. CD52 is highly expressed on the surface of T and B lymphocytes and, at lower levels, on cells of the innate immune system, namely monocytes and macrophages.\(^4\)–\(^6\) Consequently, alemtuzumab administration leads to rapid depletion of circulatory CD52-positive cells through antibody-dependent cell-mediated cytolyis and complement-dependent cytolysis.\(^7\) Subsequent to depletion, immune cells derived from hematopoietic stem cells slowly repopulate. The repopulation dynamics are distinct for different immune cell types with B lymphocytes recovering faster than T cells. B lymphocyte numbers return to the baseline level after approximately 3 months; after 12 months, they can even exceed baseline levels.\(^5\)\(^,\)\(^9\)

The trade-off for clinical efficiency of alemtuzumab is the occurrence of frequent and sometimes serious adverse events.\(^10\) The most interesting and not yet fully understood adverse events are secondary autoimmune phenomena.\(^11\)

Several case reports also described either viral or complex bacterial or fungal infections, highlighting consequences of T-cell depletion.\(^12\) Common and usually noncomplicated infections, such as pneumonia or bacterial upper respiratory tract infections fostered by hypogammaglobulinemia, have received much less attention to date. Because of new reports of immune-mediated and partly fatal cardiovascular adverse events, the European Medicines Agency (EMA) restricted the use in April 2019.

Autoantibody production leading to consecutive autoimmune phenomena after alemtuzumab treatment has already been reported; however, physiologic immunoglobulin production following alemtuzumab administration has not yet been analyzed in greater depth.

**Methods**

**Study design and setting**

Between January 2015 and December 2016, 38 patients with diagnosed active RRMS were treated with at least 2 cycles of alemtuzumab at the Neurology Clinic of the University Hospital Münster. Serum (n = 38) and CSF (n = 24) samples were collected at treatment start and at 12, 24, and 36 months after the first alemtuzumab administration. None of the patients had received previous immunosuppressive or B cell–depleting therapy, had any history of chronic (autoimmune or infective) disease other than RRMS, or experienced a clinical relapse within the 4 weeks before sample collection. Patients were interviewed and clinically examined in regular 3-monthly follow-up visits (table 1).

This study provides Class IV evidence that long-term treatment with alemtuzumab can reduce immunoglobulin levels in patients with RRMS.

**Participants**

Demographic data collected included age, sex, duration of MS before alemtuzumab therapy, baseline EDSS score, number of previous disease-modifying therapies (DMTs), and number of MS relapses within the 2 years before alemtuzumab therapy. Diagnostic data included analysis of CSF cell count, CSF protein levels, CSF lactate, serum/CSF albumin ratio, CSF and serum analysis of immunoglobulin concentrations (IgG, IgA, and IgM) including serum/CSF immunoglobulin ratios as an indicator for intrathecal synthesis of IgG, IgA, and IgM, and oligoclonal bands (OCB) as an indicator for intrathecal IgG synthesis. During alemtuzumab treatment cycles, patients were examined for opportunistic infections, and data on disease activity and MS relapses were gathered.

| Table 1 Baseline characteristics of the study cohort |
|-----------------------------------------------|
| **Patients, no.** | 38 |
| **Blood samples available, no. (%)** | 38 (100) |
| **CSF samples available, no. (%)** | 24 (63.2) |
| **Age, yr, median (range)** | 33 (18–58) |
| **Male sex, no. (%)** | 18 (47.3) |
| **MS duration, yr, median (range)** |
| Since manifestation | 4 (0–27) |
| Since diagnosis | 4 (0–17) |
| **Previous DMTs, no., median (range)** | 2 (0–6) |
| **Baseline EDSS score, median (range)** | 2.5 (0–6) |
| **Relapses within past 2 years, median (range)** | 3 (0–9) |
| **OCBs positive at baseline (%)** | 22 (79) |

Abbreviations: DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; OCB = oligoclonal band.
CSF and serum analysis
CSF and serum were analyzed using routine methods. Immediately after CSF sampling via lumbar puncture, CSF cell count, total protein, and lactate were analyzed. CSF cells were counted manually with a Fuchs-Rosenthal counting chamber. For further analyses, the residual CSF was centrifuged (145g for 15 minutes), and the supernatant was frozen at −80°C. The corresponding serum was also frozen at −80°C. CSF total protein was determined by a Bradford dye-binding procedure. Albumin, IgG, IgA, and IgM were examined in serum and CSF in the same latex-enhanced assay by kinetic nephelometry (Siemens BN ProSpec, Münster; Beckman Coulter IMMAGE, Hannover) according to the guidelines by the manufacturer. The function of the blood-CSF barrier was estimated as CSF-serum albumin quotient (QAlbumin). The age-adjusted upper reference limit of QAlbumin (QAlb) was calculated using the formula QAlb = 4 + (age in years/15). Intrathecal synthesis of immunoglobulins (IgG, IgA, and IgM) was calculated based on the method of Reiber-Felgenhauer, referring IgG, IgA, and IgM quotients to the albumin quotient. CSF and serum OCBs were determined by isoelectric focusing (Pharmacia Biotech) in polyacrylamide gels (EDC) with consecutive silver staining (GE Healthcare) according to the manufacturers’ recommendations. Five patterns of OCBs were distinguished following the recommendations of the first European consensus on CSF analysis in MS, whereas the type 2 and 3 pattern is an indicator for intrathecal IgG synthesis.

To analyze immunoglobulin changes after 3 courses of alemtuzumab, we thawed serum samples obtained immediately before additional courses. Those samples were processed differently to samples from the previous time point and were eventually not comparable to previous values. We therefore decided to also analyze matched samples from patients with MS with ongoing natalizumab therapy and treatment-naïve patients with MS, which underwent a similar thawing process to exclude process-related effects on serum immunoglobulin concentrations. To compare between groups, patients were matched for age, sex, disease duration since manifestation, and storage duration of samples. In accordance with the inclusion criteria for alemtuzumab-treated patients, none of the controls had received previous immunosuppressive or B cell–depleting therapy, and samples were obtained minimally 4 weeks after the last clinical relapse.

Statistical analysis
To compare between the groups at treatment start and at 24 months, the Mann-Whitney rank-sum test was used. To compare samples from 36 months after treatment start with respective controls, the Kruskal-Wallis test for multiple-group comparison including the Dunn post-test was used. Continuous variables (e.g., quantitative fraction of intrathecal IgG synthesis over time) were analyzed using the Wilcoxon paired test. To test categorical variables (proportion of patients with positive OCBs at different time points), The McNemar test with Edwards correction was applied. Statistical analysis was performed using SPSS 25 (IBM, CA). $p$ Values below 0.05 were considered significant.

Data availability
All authors have full access to all data sets and take full responsibility for the integrity of the data and accuracy of the data analysis. Data will be shared on request from any qualified investigator.

Results
Patient characteristics
In total, we analyzed blood samples of 38 patients treated with alemtuzumab. For 24 patients, additional CSF samples were available. The patient characteristics at baseline are summarized in table 1.

Serum IgG, IgM, and IgA concentrations of alemtuzumab-treated patients are reduced after 12 and 24 months
We measured serum immunoglobulin before the first administration of alemtuzumab and at 12 and 24 months. All patients received at least 2 cycles of alemtuzumab therapy according to SmPC. Eight patients required a third course 24 months after the first infusion due to ongoing disease activity. We measured immunoglobulin concentrations before start of each therapy course, respectively. We found a statistically significant decrease of immunoglobulin concentrations compared with baseline values for each subgroup (IgG, IgM, and IgA; figure 1, A–C). In all examined immunoglobulin subgroups, we found a stronger reduction after 24 months than after 12 months. All median values and $p$ values are listed in an additional table (table e-1, links.lww.com/NXI/A172). Within the IgA group, 3 outliers with noticeably increased values could be identified before and 12 months after the first administration of alemtuzumab. At 24 months, no outliers remained. Notably, the majority of patients showed IgG levels within the normal range. At 24 months after therapy start, only 6 patients presented with IgG levels under 7 g/L (normal value $>7$ g/L).

Intrathecal IgG synthesis decreases during alemtuzumab therapy
For the majority of cases, we observed a significant decrease of the quantitative fraction of intrathecal IgG synthesis at 12 and 24 months after the first alemtuzumab administration. Except for 1 case, the decrease was progressive over time. We identified 3 patients with rising intrathecal IgG synthesis between therapy initiation and 12 months. For these 3 patients, synthesis significantly decreased thereafter. Furthermore, median CSF IgG, IgM, and IgA concentrations significantly decreased over time. All median values and $p$ values are listed in an additional table (table e-2, links.lww.com/NXI/A172). At baseline, 79% of all patients exhibited positive OCBs in the CSF. At 12 and 24 months after therapy start, their percentage amounted to 75% ($p = 1.000$) and 71% ($p = 0.0662$), respectively. In fact, for 2 patients, OCBs were no longer detectable at 24 months (figure e-1, links.lww.com/NXI/A172).
Patients exhibit reduced serum IgG levels after the third course of alemtuzumab

Eight patients required a third course of alemtuzumab due to sustained disease activity (new relapses: 4/8; EDSS progression: 1/8, cMRI with new/enlarging T2 lesions: 7/8). We measured serum immunoglobulin levels 12 months after the third course of alemtuzumab (36 months after initiation of therapy). Unlike previous measurements, those samples underwent freezing and thawing before analysis, and our quality control indicated slight differences in 4 samples. We performed a quality control measurement of 4 samples that were both freshly analyzed and stored and found slight differences in IgG levels (5%). We therefore decided not to perform comparison between 36-month samples and other time points but compared our findings with similarly processed samples from patients having not received a third course. In addition, we included samples from naive patients with MS as further control.

Compared with patients treated twice and treatment-naive patients with MS (table e-3, links.lww.com/NXI/A172), patients with a third alemtuzumab course showed further, significant reduction of serum IgG levels, ranging from 5.0 to 7.5 g/L (p = 0.006 compared with patients with 2 courses). The majority of controls presented with serum IgG levels of about 10.0 g/L at 36 months. For the other immunoglobulin subgroups (IgM and IgA), no differences were detectable. Because specimens were thawed and serum immunoglobulin levels were measured afterward, values are comparable among each other but not with regard to reference values.

Patients with reduced immunoglobulin levels were more likely to have otitis, sinusitis, and pneumonia

In adults, the lower limit of normal for serum IgG levels is about 7 g/L. For lower values, IgG deficiency is diagnosed. For the 38

Table 2 Frequency of different infections during alemtuzumab treatment

|                  | Total events with qualified IgG measurement | Serum IgG >7 g/L in closest proximity to event | Serum IgG <7 g/L in closest proximity to event | Time from last course of ALEM, range (months) |
|------------------|---------------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------------------|
| Upper respiratory tract infection | 57                                          | 50                                            | 7                                             | 3–35                                        |
| Otitis media     | 9                                           | 3                                             | 6                                             | 13–32                                       |
| Sinusitis        | 10                                          | 2                                             | 8                                             | 11–26                                       |
| Pneumonia        | 3                                           | 0                                             | 3                                             | 14–26                                       |
| Skin infection   | 2                                           | 2                                             | 0                                             | 5–12                                        |
| Urinary tract infection | 48                                          | 42                                            | 6                                             | 2–30                                        |

Abbreviation: ALEM = alemtuzumab.

Patients with serum IgG levels >7 g/L were compared with patients with serum IgG levels <7 g/L. Numbers in columns 1-3 represent observed events. Bold numbers indicate infections associated with hypogammaglobulinemia.
Alemtuzumab-treated patients, we documented any infections as events in a 3-year follow-up. In 36/38 patients (95%) of patients, we observed infections as adverse events. Mainly, patients had upper respiratory tract or urinary tract infections (44% and 37% of all events, respectively). Several cases of otitis and sinusitis were also observed. Three individuals had pneumonia, and 2 had soft tissue infections. We analyzed IgG levels when patients presented to the neurologic department for their regular 3-monthly visit after alemtuzumab treatment. Some patients required repeated measurement. We evaluated all events for which serum IgG levels were available within a 3-month period before reported infections. We checked whether preexisting IgG deficiency was associated with an increased susceptibility toward different types of infections. In case of multiple measurements within the specified time, we included the measurement closest to onset of infection.

Within the group of patients with upper respiratory tract infections and urinary tract infections, IgG levels were above 7 g/L in the majority of cases. Patients having otitis, pneumonia, or sinusitis frequently exhibited reduced serum IgG levels during their previous examination.

Discussion

Administering alemtuzumab leads to rapid depletion of circulating CD52–positive immune cells. However, immune cells in lymphoid organs are less affected. T cells recover within 11–12 months, whereas the B-lymphocyte count typically normalizes within 6 months posttreatment. However, Jones and colleagues observed early T-cell recovery after alemtuzumab treatment, largely driven by homeostatic expansion of cells that escaped depletion. Furthermore, they demonstrated that homeostatic proliferation increased the risk of secondary autoimmunity. Between 30% and 41% of alemtuzumab-treated patients develop thyroid autoimmune disease. Less common, but potentially more critical, are immune thrombocytopenia and glomerulonephritis. A possible mechanism behind secondary autoimmunity is the faster repopulation of B cells in the absence of effective T-cell regulation in individuals with genetic susceptibility for autoimmunity. However, T cell–mediated secondary autoimmune phenomena have also been described and the mechanisms of reeducation of immune regulatory networks after CD52 depletion remain largely elusive.
alemtuzumab treatment. CD19+CD24hiCD38hi and CD19+PD-B-cell distribution shifts toward a naive phenotype following B-lymphocyte repopulation. Recently, it has been shown that immunoglobulin concentrations in serum independent from levels despite normalized B-cell counts indicates a decrease of initiation (IgM and IgA concentrations increased 36 months after therapy). In patients without a third course, IgG but not dose (limiting Th1 and Th17 differentiation and maintaining regulatory T cells). This may serve as an explanation for continuously low immunoglobulin concentrations. Wray and colleagues found that concentrations of immunoglobulins to common viruses, as shown by Clark and colleagues, result from CD52-negative antibody-secreting long-lived plasma cells. While we did not measure specific antibodies, the total immunoglobulin concentration decreased in our patient cohort.

The ongoing reduction of IgG levels in peripheral blood seems to be of clinical relevance. Among our 38 patients, those with IgG values below 7 g/L showed a higher susceptibility to develop infections such as pneumonia, sinusitis, and otitis (table 2), whereas the more common infections such as upper respiratory tract and urinary tract infections were not related to reduced serum IgG levels. It has to be noted that we did not differentiate between mild hypogammaglobulinemia (defined as IgG <7 g/L) and severe hypogammaglobulinemia (defined as IgG <4 g/L). In a study of 389 patients with secondary hypogammaglobulinemia, Bloet and colleagues detected no significant difference between patients with mild and severe hypogammaglobulinemia regarding their infectious risk, which indicates that hypogammaglobulinemia generally increases the risk of infection. However, Furst stated that very low levels of IgG are indeed associated with a heightened risk of infections, but he also demonstrated that less severe hypogammaglobulinemia (>5 g/L) appears to be tolerated in most subjects.

Within our cohort, pneumonia, sinusitis, and otitis were observed much later following alemtuzumab compared with urinary tract infections and upper respiratory tract infections, which occurred early after infusions. This could indicate differences in underlying pathophysiology. Hypogammaglobulinemia is also known as a relevant risk factor for infections with cytomegalovirus (CMV). Recently, few case reports have described CMV infections in alemtuzumab patients. Although an increased risk of infections is clearly acknowledged in phases around infusions, a clear signal for an increased risk of infections has not been reported to date. Other depleting antibodies used to treat autoimmune diseases, such as the anti-CD20 antibody rituximab, also lead to a significant decrease of blood immunoglobulin levels during therapy. However, several studies on patients with rheumatoid arthritis (RA) treated with rituximab could demonstrate that patients with below normal immunoglobulin levels did not have more serious infections than patients with normal immunoglobulin levels.

Our results appear to be in contrast to the findings of McCarthy et al., who performed a pilot study regarding immunologic memory to common viruses and responses to vaccinations in 24 patients with prior alemtuzumab treatment. Their patients exhibited a normal humoral response to diphtheria, tetanus, and poliomyelitis vaccine, haemophilus influenzae type b and meningococcal group C conjugate vaccine, and pneumococcal...
polysaccharide vaccine with normal IgG titers. One possible explanation might be that in contrast to the McCarthy cohort, most of our patients had received multiple immunomodulatory therapies before alemtuzumab administration. Being a real-world cohort with patients including complex history of MS treatment despite exclusion of patients with a history of mitoxantrone, azathioprine or anti-CD20 therapy might also explain why the observation of developing hypogammaglobulinemia has not been made in the phase 3 trials and their respective extension studies.23 Age-dependent effects in our cohort are rather unlikely as the median even undercuts the median age of patients from CARE-MS II. However, real-world cohorts have shown different frequencies or even entities of adverse events following immunomodulatory treatment with progressive multifocal leukoencephalopathy following natalizumab treatment being rapidly present in one’s mind.34

If immunoglobulin levels would be monitored during and following alemtuzumab therapy, especially in patients with multiple previous DMTs, patients with markedly reduced IgG levels could be identified, and possibly, a prophylactical antibiotic treatment or immunoglobulin substitution therapy could be initiated to prevent serious infections in those patients. Besides McCarthy et al., another group assessed antigenic responses following influenza, polyvalent pneumococcus vaccine (PPV23) and combined diphtheria/tetanus/polio virus vaccines in patients with RA who had been treated with alemtuzumab 20 years ago. Similar levels of seroprotection following poliovirus (P1–P3), tetanus, and diphtheria vaccination were observed for alemtuzumab-treated patients and controls.35 As the nature of the observed infections in our cohort (pneumonia, otitis, and sinusitis) indicates that encapsulated bacteria such as *Streptococcus pneumoniae* might be responsible, PPV23 vaccination before alemtuzumab induction seems reasonable.

An interesting aspect of our study is the parallel measurement of CSF immunoglobulins, in addition to the periphery. Because of the decrease of serum IgG concentrations, reduction of IgG levels measured in CSF is to be expected. Of interest, the percentage of intrathecal IgG synthesis itself is lowered in nearly all patients (figure 2). This indicates that reduction of CSF IgG is not merely a consequence of decreased serum IgG concentrations and could suggest that alemtuzumab inhibits the autoimmune process within the CNS. This is also reflected by the disappearance of OCBs in 2 patients (figure 2).

Within our cohort, 8 patients required a third treatment cycle because of ongoing/returning clinical or paraclinical disease activity. They exhibited significantly reduced serum IgG concentrations compared with matched controls who received only 2 treatment cycles and also with treatment-naive patients with MS (figure 3). Therefore, the decrease in serum IgG concentrations is not merely a consequence of thawing the specimens. The fact that patients with 3 treatment courses presented with lower IgG concentrations is not surprising, as they received a higher overall dose of alemtuzumab and their last treatment took place only 12 months ago. Of interest, other immunoglobulin subgroups were not affected. In addition, it can be observed that serum IgG levels of alemtuzumab patients without a third treatment course obviously normalized over time, as they do not differ from IgG concentrations of untreated patients with MS (figure 3).

Our study has several limitations. First, this work is based on a retrospective analysis of clinical data. Because of the nature of this investigation, no causal relations can be interpreted. Moreover, the number of cases especially of patients with a third alemtuzumab course is limited, and their samples have been thawed before the analysis of immunoglobulin levels. As a result, the findings need to be verified in larger samples. In addition, real-world cohorts are needed to determine the exact temporal expansion of hypogammaglobulinemia following alemtuzumab treatment.

### Conclusion

We could demonstrate reduced concentrations for all immunoglobulin subgroups at 12, 24, and 36 months after initiation of alemtuzumab therapy. Patients requiring a third treatment cycle due to ongoing disease activity had the most severe drop in IgG concentrations. Reduced IgG concentrations were associated with an increase in pneumonia, otitis, and sinusitis. We therefore suggest that serum IgG levels should be monitored at least in those patients receiving more than 2 treatment courses of alemtuzumab. In addition, we recommend a pretreatment pneumococci vaccination. The decreased intrathecal IgG production in the CSF suggests that alemtuzumab effectively suppresses the autoimmune process within the CNS.

### Study funding

The study was financially supported by Sanofi Genzyme (ALAIN01 to H. Wiendl, T. Ruck, and S.G. Meuth) and the Competence Network Multiple Sclerosis (01GI1603D, PROGRAMMS to T. Ruck and S.G. Meuth).

### Disclosure

N. Möhn reports no disclosures. S. Pfeuffer received travel grants from Sanofi Genzyme and Merck Serono, lecturing honoraria from Sanofi Genzyme, Mylan Healthcare, and Biogen, and research support from Diamed and Merck Serono. T. Ruck received travel grants and financial research support from Sanofi Genzyme and Novartis and received honoraria for lecturing from Roche, Merck, Genzyme, Biogen, and Teva. C.C. Gross received speaker honoraria, travel expenses for attending meetings, and research support from Bayer, Biogen, Genzyme, MyLan, and Novartis. T. Skripuletz received honoraria for lecturing and travel expenses for attending meetings from Bayer Vital, Biogen, Merck Serono, Novartis, Roche, and Sanofi-Aventis. L. Klotz received honoraria for lecturing and travel expenses for attending meetings and has received financial research support from Biogen ldec, Genzyme, Janssen, Merck Serono, Novartis, Roche, Sanofi-Aventis, and Teva. H. Wiendl received honoraria for acting as a member of scientific advisory boards and as a consultant for...
Appendix (continued)

| Name                  | Location                          | Role                                | Contribution                      |
|-----------------------|-----------------------------------|-------------------------------------|-----------------------------------|
| Thomas Skripuletz, MD, Prof | Hannover Medical School, Hannover, Germany | Author                             | Critical revision of the manuscript for intellectual content |
| Luisa Klotz, MD, Prof | University of Münster, Münster, Germany | Author                             | Critical revision of the manuscript for intellectual content |
| Heinz Wiendl, MD, Prof | University of Münster, Münster, Germany | Author                             | Critical revision of the manuscript for intellectual content |
| Martin Stangel, MD, Prof | Hannover Medical School, Hannover, Germany | Author                             | Study concept and design and critical revision of the manuscript for intellectual content |
| Sven G Meuth, MD, Prof | University of Münster, Münster, Germany | Author                             | Study concept and design and critical revision of the manuscript for intellectual content |

References

1. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819–1828.
2. Coles AJ, Compton DA, Selmy JW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786–1801.
3. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78:1069–1078.
4. Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174–7179.
5. Hall G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35:118–127.
6. Hall G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001;3:137–143.
7. Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci 2015;16:1414–16439.
8. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98–108.
9. Thompson SA, Jones JL, Cox AL, Compton DA, Coles AJ. B-cell reconstitution and B cells after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 2010;30:99–105.
10. Menge T, Stöve O, Kiesee BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology 2014;83:87–97.
11. Hartung HP, Alkaz O, Alkaz AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler 2015;21:22–34.
12. Brownlee WJ, Chatzay J. Opportunistic infections after alemtuzumab: new cases of nocardial infection and cytomegalovirus syndrome. Mult Scler 2017;23:876–877.
13. Schwenkenbecher P, Chacko LP, Würster U, et al. Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis. BMC Neurol 2016;16:136.
14. Reiber H. Cerebrospinal fluid—physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler 1998;4:99–107.
15. Andersson M, Alvarez-Cermeto J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994;57:897–902.
16. Turner MJ, Lamorte MJ, Chretien N, et al. Immune status following alemtuzumab treatment in human CD52 transgenic mice. J Neuroimmunol 2013;261:29–36.
17. Jones JL, Thompson SAJ, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A 2013;110:20200–20205.
18. Baker D, Herrod SS, Alvarez-Gonzalez C, Giannouli G, Schmitzer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 2017;74:961–969.
19. Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, et al. Vitiligo after alemtuzumab treatment: secondary autoimmunity is not all about B cells. Neurology 2018;91:e2233–e2237.
20. Wiendl H, Calabresi PA, Meuth SG. Defining response profiles after alemtuzumab: rare paradoxical disease exacerbation. Neurology 2018;90:309–311.
21. Kim Y, Kim G, Shin HJ, et al. Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis. J Neuroinflammation 2018;15:300.

22. Flores-Borja F, Bosma A, Ng D, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Clin Rheumatol 2017;36:2743–2750.

23. Wray S, Havrdova E, Snyderman DR, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler 2018;25:1605–1617.

24. Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012;4:117.

25. Kumar S, Kimlinger TK, Lust JA, Donovan K, Witzig TE. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 2003;102:1075–1077.

26. Blot M, Boyer P, Samson M, et al. Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. Eur J Intern Med 2014;25:837–842.

27. Furst DE. Serum immunoglobulins and risk of infection: how low can you go?. Semin Arthritis Rheum 2009;39:18–29.

28. Clerico M, De Mercanti S, Artusi CA, Durelli L, Naisbit RT. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler 2013;20:874–876.

29. Einarsson JT, Evert M, Geborek P, Saxne T, Lundgren M, Kapetanovic M. Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies. Clin Rheumatol 2017;36:2743–2750.

30. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625–2632.

31. van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496–1502.

32. van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Long-term safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 2015;42:1761–1766.

33. McCarthy CL, Tuohy O, Compston DA, Kumazarutane DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology 2013;81:872–876.

34. Schwab N, Schneider-Hohendorf T, Mezler N, Cutter G, Wienh H. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 2017;88:1197–1205.

35. Cooles FA, Anderson AE, Dreyton T, et al. Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies. Arthritis Res Ther 2016;18:302.
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
Nora Möhn, Steffen Pfeuffer, Tobias Ruck, et al.
Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000654

This information is current as of December 11, 2019

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/7/2/e654.full.html

References
This article cites 35 articles, 6 of which you can access for free at:
http://nn.neurology.org/content/7/2/e654.full.html#ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
http://nn.neurology.org/content/7/2/e654.full.html#otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Class IV
http://nn.neurology.org/cgi/collection/class_iv
Multiple sclerosis
http://nn.neurology.org/cgi/collection/multiple_sclerosis

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.